<div id="readability-page-1"><p>Tema Etfs LLC increased its stake in shares of  Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 307.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor  owned 86,301 shares of the company's stock after acquiring an additional 65,132 shares during the quarter. Tema Etfs LLC owned about 0.10% of Syndax Pharmaceuticals worth $808,000 at the end of the most recent quarter.</p><div><p><span></span><span>Get <strong>Syndax Pharmaceuticals</strong> alerts:</span></p></div><p>Other large investors also recently bought and sold shares of the company. Franklin Resources Inc. increased its position in shares of  Syndax Pharmaceuticals by 14.5% during the second quarter. Franklin Resources Inc. now owns 2,359,677 shares of the company's stock worth $22,098,000 after purchasing an additional 298,272 shares in the last quarter.  Geode Capital Management LLC increased its position in  Syndax Pharmaceuticals by 1.3% during the second quarter. Geode Capital Management LLC now owns 2,049,350 shares of the company's stock worth $19,195,000 after buying an additional 26,365 shares during the period.  Aisling Capital Management LP lifted its stake in  Syndax Pharmaceuticals by 28.5% in the second quarter. Aisling Capital Management LP now owns 1,316,806 shares of the company's stock valued at $12,325,000 after buying an additional 291,806 shares during the last quarter.  Algert Global LLC boosted its holdings in shares of  Syndax Pharmaceuticals by 12.6% in the first quarter. Algert Global LLC now owns 884,600 shares of the company's stock valued at $10,867,000 after acquiring an additional 98,968 shares during the period.  Finally, Candriam S.C.A. boosted its holdings in shares of  Syndax Pharmaceuticals by 49.9% in the second quarter. Candriam S.C.A. now owns 675,085 shares of the company's stock valued at $6,322,000 after acquiring an additional 224,650 shares during the period. </p><h2>Syndax Pharmaceuticals Stock Up 2.9%</h2><p>SNDX opened at $20.32 on Friday. The company has a debt-to-equity ratio of 2.78, a current ratio of 4.64 and a quick ratio of 4.42. Syndax Pharmaceuticals, Inc. has a 12 month low of $8.58 and a 12 month high of $20.59. The stock has a market capitalization of $1.77 billion, a P/E ratio of -5.63 and a beta of 0.48. The business has a 50 day simple moving average of $16.30 and a 200-day simple moving average of $13.57. </p><p>Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings data on Monday, November 3rd. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.04. The firm had revenue of $45.87 million during the quarter, compared to analysts' expectations of $49.08 million. Syndax Pharmaceuticals had a negative return on equity of 160.60% and a negative net margin of 279.31%.Syndax Pharmaceuticals's revenue was up 266.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.98) earnings per share.  On average, equities analysts anticipate that  Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Several research firms recently commented on SNDX. Barclays upped their price target on shares of Syndax Pharmaceuticals from $22.00 to $35.00 and gave the company an &#34;overweight&#34; rating in a research report on Monday, November 24th. The Goldman Sachs Group upped their target price on shares of Syndax Pharmaceuticals from $20.00 to $24.00 and gave the company a &#34;buy&#34; rating in a report on Friday, September 5th. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Syndax Pharmaceuticals in a research note on Monday. Stifel Nicolaus initiated coverage on Syndax Pharmaceuticals in a research report on Wednesday, September 10th. They issued a &#34;buy&#34; rating and a $44.00 price target on the stock. Finally, Wall Street Zen cut Syndax Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday. One research analyst  has rated the stock with a Strong Buy rating, nine have issued  a Buy rating, one  has issued  a Hold rating and one  has issued  a Sell rating to the company. According to data from MarketBeat, Syndax Pharmaceuticals currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $37.20.</p><p><b>Read Our Latest Stock Analysis on SNDX</b></p><h2>Insiders Place Their Bets</h2><p>In other news, CEO Michael A. Metzger sold 157,307 shares of the business's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $16.41, for a total transaction of $2,581,407.87. Following the sale, the chief executive officer owned 298,661 shares of the company's stock, valued at $4,901,027.01. The trade was a 34.50% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Insiders own  4.10% of the company's stock. </p><h2>Syndax Pharmaceuticals Profile</h2> (Free Report)<p>Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).</p><h2>Read More</h2><ul><li>Five stocks we like better than Syndax Pharmaceuticals</li><li>NYSE Stocks Give Investors a Variety of Quality Options </li><li>Gates Foundation Sells MSFT Stock—Should Investors Be Worried?</li><li>High Flyers: 3 Natural Gas Stocks for March 2022</li><li>MarketBeat Week in Review – 12/1 - 12/5</li><li>A Deeper Look at Bid-Ask Spreads</li><li>Rocket Lab’s Big Rebound? Analysts Suggest the Dip's a Gift</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05EWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05EWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Syndax Pharmaceuticals Right Now?</h2><p>Before you consider Syndax Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.</p><p>While Syndax Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SNDX

<p>Tema Etfs LLC increased its stake in Syndax Pharmaceuticals by 307.7% in Q2, owning 86,301 shares worth $808,000. Other investors also boosted their holdings. Syndax's stock rose 2.9%, with a market cap of $1.77 billion. Analysts have mixed ratings, with a consensus of "Moderate Buy" and an average target price of $37.20. CEO Michael Metzger sold shares worth $2.58 million.</p>

Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Tema Etfs LLC